Last reviewed · How we verify
NCT07434401
α-N-acetylgalactosaminidase in Methamphetamine Psychosis
trial in Methamphetamine Use Disorder in 93 participants. Completed in 31 August 2025.
31 August 2025
Quick facts
| Lead sponsor | Elazığ Mental Health and Diseases Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 93 |
| Start date | 1 May 2025 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Methamphetamine Use Disorder — all drugs for Methamphetamine Use Disorder →
- Methamphetamine-induced Psychosis — all drugs for Methamphetamine-induced Psychosis →
Sponsor
Elazığ Mental Health and Diseases Hospital
Who can join
Adults 18 to 65, male only, with Methamphetamine Use Disorder or Methamphetamine-induced Psychosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This cross-sectional observational cohort study examined serum α-N-acetylgalactosaminidase levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study aimed to determine whether decreased α-N-acetylgalactosaminidase levels are associated with psychotic symptoms in methamphetamine users.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07434401
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Methamphetamine Use Disorder
Currently open trials in the same condition.
- NCT07226596 — Non-Abstinence Outcomes in Methamphetamine Use Disorder · NA · recruiting
- NCT07450027 — LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis · recruiting
- NCT06989853 — Methamphetamine and Troriluzole · EARLY_PHASE1 · recruiting
- NCT07459244 — ECG Findings in Methamphetamine Use · recruiting
- NCT06712446 — A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder · NA · recruiting
Other Elazığ Mental Health and Diseases Hospital trials
Trials by the same sponsor.
- NCT07459270 — Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use · not yet recruiting
- NCT07451821 — Cognitive Disengagement Syndrome in Functional Neurological Symptom Disorder · not yet recruiting
- NCT07447960 — LRFN5 and OLFM4 in Schizoaffective Disorder · not yet recruiting
- NCT07450027 — LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis · recruiting
- NCT07444879 — IL-33, sST2, and CRP in Panic Disorder · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07434401 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Elazığ Mental Health and Diseases Hospital
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07434401.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing